Since autologous T cells have compromised immune function while allogeneic T cells risk interception by NK cells or cause severe GvHD, Degagné et al., 2024 explored immune cloaking methods by engineering B2M-HLA-E onto CB-011 (anti-BCMA) CAR T cells to enable safer and effective treatment for multiple myeloma [38]. Here, B2M is linked to plasma cell myeloma.